Eric Easom, AN2 Therapeutics CEO
March 7, 2022 10:42 AM EST
Financing

A lone biotech braves the bone-dry IPO fore­cast, seek­ing to go pub­lic amidst a bar­ren land­scape

Max Gelman

Senior Editor

Just two months af­ter putting to­geth­er a pri­vate fund­ing round, a Cal­i­for­nia biotech is head­ed to Nas­daq.

AN2 Ther­a­peu­tics filed its S-1 pa­per­work on …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Pfiz­er hires ex-FDA deputy Pa­trizia Cavaz­zoni as chief med­ical of­fi­cer

Post-Hoc: Phar­ma CEOs' al­ter­na­tive re­al­i­ty with Trump

Pfiz­er wants in on Sum­mit’s goal to beat Keytru­da via ADC com­bos

Some FDA med­ical de­vice staff re­in­stat­ed just days af­ter re­ceiv­ing pink slips

FDA lifts hold on En­trada's Duchenne drug af­ter two years

sponsored

How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try

A service from the Financial Times